Hematologic Oncology | Specialty

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Emerging Combinations for FLT3-Mutated AML

May 5th 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.

BCL2 Inhibitor Combinations in FLT3-Mutated AML

May 5th 2021

A discussion on the use of venetoclax combinations with FLT3 inhibitors, especially in older patients with FLT3-mutated acute myeloid leukemia.

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

May 5th 2021

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

May 4th 2021

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Dr. Ansell on Challenges With PET Scans in Hodgkin Lymphoma

May 4th 2021

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Unmet Needs in GVHD

May 4th 2021

Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.

Safety and Efficacy of PI3K Inhibitors in MZL and FL

May 4th 2021

Expert hematologist-oncologists share insights about the role of PI3K inhibition and immunosuppression in indolent non-Hodgkin lymphoma and review the safety and efficacy of idelalisib, duvelisib, and copanlisib.

Second-Line Chemoimmunotherapy for MZL and FL

May 4th 2021

Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, consider treatment options for patients with relapsed/refractory disease after first-line chemoimmunotherapy.